JP Morgan Chase’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-195,100
| Closed | -$4.2M | – | 7873 |
|
|
2025
Q4 | $4.2M | Sell |
195,100
-62,300
| -24% | -$1.31M | ﹤0.01% | 3488 |
|
|
2025
Q3 | $4.96M | Buy |
257,400
+137,400
| +115% | +$2.45M | ﹤0.01% | 3371 |
|
|
2025
Q2 | $2.05M | Buy |
120,000
+50,000
| +71% | +$2.13M | ﹤0.01% | 3901 |
|
|
2025
Q1 | $4.47M | Hold |
70,000
| – | – | ﹤0.01% | 3254 |
|
|
2024
Q4 | $8.51M | Sell |
70,000
-80,000
| -53% | -$9.8M | ﹤0.01% | 2846 |
|
|
2024
Q3 | $18.7M | Buy |
+150,000
| New | +$20.7M | ﹤0.01% | 2048 |
|
|
2024
Q2 | – | Sell |
-55,000
| Closed | -$7.12M | – | 7729 |
|
|
2024
Q1 | $7.12M | Sell |
55,000
-162,400
| -75% | -$19.9M | ﹤0.01% | 2787 |
|
|
2023
Q4 | $21M | Buy |
217,400
+139,100
| +178% | +$13.3M | ﹤0.01% | 1819 |
|
|
2023
Q3 | $9.49M | Buy |
78,300
+43,500
| +125% | +$4.92M | ﹤0.01% | 2294 |
|
|
2023
Q2 | $3.99M | Sell |
34,800
-1,200
| -3% | -$155K | ﹤0.01% | 3049 |
|
|
2023
Q1 | $4.96M | Buy |
36,000
+28,500
| +380% | +$3.7M | ﹤0.01% | 2827 |
|
|
2022
Q4 | $972K | Sell |
7,500
-1,600
| -18% | -$185K | ﹤0.01% | 4063 |
|
|
2022
Q3 | $1.01M | Buy |
+9,100
| New | +$917K | ﹤0.01% | 3987 |
|
|
2022
Q2 | – | Sell |
-100,000
| Closed | -$7.81M | – | 6869 |
|
|
2022
Q1 | $7.81M | Sell |
100,000
-73,500
| -42% | -$5.63M | ﹤0.01% | 2618 |
|
|
2021
Q4 | $15.6M | Sell |
173,500
-209,400
| -55% | -$17.9M | ﹤0.01% | 2038 |
|
|
2021
Q3 | $35.4M | Buy |
+382,900
| New | +$29.5M | ﹤0.01% | 1361 |
|
|
2021
Q1 | – | Sell |
-417,600
| Closed | -$71.2M | – | 6338 |
|
|
2020
Q4 | $71.2M | Buy |
417,600
+415,000
| +15,962% | +$61.5M | 0.01% | 925 |
|
|
2020
Q3 | $367K | Buy |
+2,600
| New | +$395K | ﹤0.01% | 4116 |
|
|
2020
Q1 | – | Sell |
-47,600
| Closed | -$6.14M | – | 5701 |
|
|
2019
Q4 | $6.14M | Buy |
+47,600
| New | +$4.8M | ﹤0.01% | 2529 |
|
|
2019
Q3 | – | Sell |
-29,500
| Closed | -$3.83M | – | 5943 |
|
|
2019
Q2 | $3.83M | Sell |
29,500
-6,800
| -19% | -$826K | ﹤0.01% | 2862 |
|
|
2019
Q1 | $4.33M | Buy |
36,300
+9,300
| +34% | +$1.2M | ﹤0.01% | 2698 |
|
|
2018
Q4 | $2.95M | Sell |
27,000
-17,000
| -39% | -$2.13M | ﹤0.01% | 2985 |
|
|
2018
Q3 | $7.11M | Sell |
44,000
-158,000
| -78% | -$21.6M | ﹤0.01% | 2477 |
|
|
2018
Q2 | $26.7M | Buy |
+202,000
| New | +$19M | 0.01% | 1373 |
|
|
2017
Q4 | – | Sell |
-101,000
| Closed | -$4.76M | – | 5570 |
|
|
2017
Q3 | $4.76M | Buy |
+101,000
| New | +$4.04M | ﹤0.01% | 2599 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
JP Morgan Chase's SRPT Position: Q1 2026 in Review
JP Morgan Chase reduced its Sarepta Therapeutics (SRPT) stake by 5.5% in Q1 2026, selling an estimated $790K and leaving 703,191 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2363.
JP Morgan Chase first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $559M in Q3 2023. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- JP Morgan Chase held 703,191 shares of Sarepta Therapeutics worth $14.4M as of Q1 2026.
- JP Morgan Chase sold 40,797 Sarepta Therapeutics shares in Q1 2026, an estimated $790K.
- Sarepta Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2363 holding.
- JP Morgan Chase first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
- JP Morgan Chase's Sarepta Therapeutics position peaked at $559M in Q3 2023.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.